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Abstract 
Background: A few studies have reported the association between asthma and osteoporosis. We aimed to analyze 
the association of asthma and its subgroups with osteoporosis in the Korean adult population.
Methods: We used the health examinee (HEXA) data from the Korean Genome and Epidemiology Study (KoGES) 
obtained between 2004 and 2016. We included 162,579 participants (n = 3,160 with asthma; n = 159,419 controls) 
who reported their previous histories of asthma and osteoporosis. The participants were categorized into 3 groups 
based on asthma management: participants who did not need further treatment due to controlled symptoms (well 
controlled); participants with ongoing treatment (being treated); participants who were not treated even though they 
had symptoms (not being treated). Multiple logistic regression analyses were used to calculate the adjusted odds 
ratios (aORs) with 95% confidence intervals (CIs) for osteoporosis. Subgroup analyses for age and sex were conducted.
Results: The prevalence of osteoporosis was higher in patients with asthma (13.6%) than in controls (6.8%). In 
the full‑adjusted model, the aORs for osteoporosis were 1.74 (95% CI 1.55–1.94, P < 0.001) in patients with asthma 
compared to controls. There were consistent findings across the age and sex subgroups. The aORs for osteoporosis 
were 1.43 (95% CI 1.10–1.86, P = 0.008) in the well‑controlled asthma group; 1.55 (95% CI 1.28–1.89, P < 0.001) in the 
being treated asthma group; and 1.96 (95% CI 1.66–2.31, P < 0.001) in the not being treated asthma group compared 
to the control group.
Conclusion: Asthma was associated with osteoporosis in the Korean adult population. Patients with asthma not 
being treated showed the highest ORs for osteoporosis.
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Background
Osteoporosis is characterized by low bone mass and bone 
fragility, which increases the risk of bone fracture [1]. The 
prevalence of osteoporosis among adults aged ≥ 50 years 
in the USA was estimated at 16.0% and 29.9% in men and 
women, respectively [2]. The Korean National Health and 
Nutrition Examination Survey conducted between 2008 
and 2011 reported that the prevalence of osteoporosis 
in the Korean population aged ≥ 50  years was 7.3% and 
38.0% in males and females, respectively [3].
Asthma is the most prevalent chronic inflammatory 
airway disease, which involves high morbidity and 
mortality rates in severe cases. It is important to 
recognize the comorbidities since these can complicate 
the clinical treatment of patients with asthma in various 
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ways. Asthma has been reported to be associated with 
several other chronic diseases, including diabetes, 
metabolic syndrome, cardiovascular disease, rheumatoid 
arthritis, and psychiatric disease [4–8]. In Scotland, a 
population-based cross-sectional analysis reported that 
62.6% and 46.23% of adults with and without asthma, 
respectively, had ≥ 1 comorbidity; moreover, 16.3% and 
8.7% of adults with and without asthma, respectively, 
had > 4 comorbidities [9]. The etiology of asthma 
co-morbidities could be associated not only with asthma, 
but with other morbidities and common mechanisms, as 
well as environmental and genetic risk factors [4, 10].
Recent studies have demonstrated the role of systemic 
inflammatory response seen in chronic airway disease 
in osteoporosis development [11–13]. Inflammatory 
cytokines, including tumor necrosis factor (TNF)-α and 
interleukin (IL)-6, act as osteoclast stimulants, which 
promotes bone resorption. However, a few studies 
have reported the association of asthma itself with 
osteoporosis. A cross-sectional healthcare center-based 
study on Korean adults reported that the proportion 
of patients with osteopenia or osteoporosis was much 
higher in the airway hyper-responsiveness (AHR)-
positive group than in the AHR-negative group (odds 
ratio [OR] = 1.715, 95% confidence interval [CI] 1.252–
2.349), as well as in the ever-asthma group than in 
the never-asthma group (OR = 1.526, 95% CI 1.120–
2.079), except in patients with a history of systemic 
corticosteroid use [14]. A cross-sectional hospital-
based study on USA adults showed that the emergency 
department visit of patients with versus without asthma 
were associated with higher odds of osteoporosis (1.85, 
95% CI 1.82–1.88) [15]. However, the studies involved a 
small sample size or were hospital-based analyses.
We aimed to analyze the association between asthma 
and osteoporosis in the Korean adult population. Further, 
we aimed to determine the different effects of asthma 
on osteoporosis based on the condition of asthma 
management. The management of patients with asthma 
was classified as well controlled, being treated, and not 
being treated.
Methods
Study population and data collection
The ethics committee of Hallym University (2019-02-
020) approved the use of these data. The requirement for 
written informed consent was waived by the Institutional 
Review Board. This cross-sectional study used the data 
of Health Examinee (HEXA) population-based cohort 
among the Korean Genome and Epidemiology Study 
(KoGES), which is a consortium project consisting of 
six prospective cohort studies (i.e., the population-
based cohorts: the community-based KoGES_Ansan 
and Ansung study, the urban community-based 
KoGES_health examinee (HEXA) study, and the rural 
community-based KoGES_cardiovascular disease 
association study (CAVAS); the gene-environment 
model studies: the KoGES_twin and family study, 
the KoGES_immigrant study and KoGES_emigrant 
study). The KoGES HEXA study included participants 
aged ≥ 40 years old who visited the institutions, which are 
mainly general hospitals in the metropolitan areas and 
major Korean cities. The data comprised of baseline data 
obtained in 39 sites from 2004 to 2013 and follow-up data 
obtained from 2012 to 2016. Details on data collection 
have been previously described [16].
Participant selection
Among the 173,209 participants, we excluded 
participants with missing records regarding height or 
weight (n = 698), smoking history (n = 494), drinking 
alcohol habit (n = 1463), nutrition records (n = 1994), 
osteoporosis (n = 101), and asthma history (n = 5880). 
The number of missing records of asthma history 
are many because asthma was not surveyed in 2004. 
Finally, we included 3160 patients with asthma and 
159,419 controls (with no history of asthma) (Fig.  1). 
Subsequently, we performed a between-group analysis of 
the history of osteoporosis (primary objective). Further, 
we analyzed the history of osteoporosis according to the 
condition of asthma management (secondary objective). 
We excluded 7073 participants from both groups for 
lacking treatment records obtained in 2008.
Survey
Trained interviewers obtained information regarding 
the participants’ previous histories of asthma and 
osteoporosis. If the participants answered ‘yes’ to the 
question, they were then asked about the current status 
of management. The participants were categorized into 
the following three groups based on the status of asthma 
management: participants who were told by a medical 
doctor that medical treatment was not required due to 
resolution of symptoms (well controlled); participants 
undergoing treatment (being treated); and participants 
with untreated symptoms (not being treated). The body 
mass index (BMI) was calculated as kg/m2 using the 
measured height and weight values. Smoking history 
was categorized as non-smoker (< 100 cigarettes on 
entire life), past smoker (quit for > 1  year), and current 
smoker. Drinking alcohol habits were categorized as non-
drinker, past drinker, and current drinker. Nutritional 
intake (Total calories [kcal/day], Protein [g/day], Fat [g/
day], Carbohydrate [g/day], Calcium [mg/d], Phosphorus 
[mg/d], and Potassium [mg/d]) was surveyed using a 
food-frequency questionnaire, which was previously 
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validated [17]. Income groups were categorized 
according to their household incomes as follows: non-
respondent, low income (< ~$2000 per month), middle 
income (~ $2000–$3999 per month), and high income 
(~ ≥ $4000 per month).
Statistical analyses
A Chi square test was used to compare the sex 
proportion, income group, smoking status, and 
drinking alcohol history. An independent T test was 
used to compare age, BMI, and nutritional intake. A 
logistic regression model was used to analyze the OR 
of asthma for osteoporosis as the primary objective. 
Moreover, we employed a crude and adjusted model 
(age, sex, income group, BMI, smoking, alcohol 
consumption, and nutritional intake [total calories, 
protein, fat, carbohydrate, calcium, phosphorus, and 
potassium]). In the age-based subgroup analyses, 
the median age was determined by using the dividing 
point (< 53 years old and ≥ 53 years old). Regarding the 
secondary objective, a logistic regression model was 
used to calculate the ORs of asthma treatment status 
(well controlled, being treated, and not being treated 
compared to the controls) for osteoporosis.
Two-tailed analyses were conducted with statistical 
significance set at P < 0.05. Statistical analyses were 
performed using SPSS v. 24.0 (IBM, Armonk, NY, 
USA).
Fig. 1 A schematic illustration of the participant selection process that was used in the present study. A total of 162,579 participants were enrolled
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Results
Table  1 presents the general characteristics of the 
participants. Patients with asthma were more likely 
to be older, female, have higher BMI, lower income, 
non-smokers, and non-alcohol drinkers (all P < 0.001). 
Among the nutritional factors, there was a significant 
between-group difference in the amount of total calories 
(P = 0.002), protein (P < 0.001), fat (P < 0.001), and 
phosphorus (P = 0.003). The prevalence of osteoporosis 
was higher in participants with asthma (13.6%) than in 
controls (6.8%) (P < 0.001).
In multiple logistic regression analyses, when adjusted 
for risk factors that showed significant association with 
osteoporosis in univariate analysis (i.e. age, sex, BMI, 
income, smoking, alcohol consumption, and nutritional 
intake, Additional file  1), there was a significant 
association of asthma with osteoporosis (Table  2). 
In the asthma group, there was a significant increase 
in osteoporosis with ORs of 1.74 (95% CI 1.55–1.94, 
P < 0.001) for the full-adjusted model. Sex- and age-based 
subgroup analyses showed comparable results.
The adjusted OR for osteoporosis were 1.43 (95% 
CI 1.10–1.86, P = 0.008), 1.55 (95% CI 1.28–1.89, 
P < 0.001), 1.96 (95% CI 1.66–2.31, P < 0.001), in the well-
controlled, being treated, and not being treated asthma 
groups, respectively (Table  3). We performed sex- and 
age-based subgroup analyses (Table  3). The adjusted 
ORs for osteoporosis in the subgroups of women and 
age ≥ 53  years were higher than those in the control 
group, regardless of the asthma management condition. 
In the subgroup of < 53  years (1.75, 95% CI 1.18–2.58, 
P = 0.005) and men (3.43, 95% CI 1.95–6.04, P < 0.001), 
the adjusted ORs for osteoporosis were higher in the not-
being treated asthma group than in the control group.
Discussion
We observed a positive association of asthma with 
osteoporosis. Compared with the control group, the 
adjusted OR was highest in the not being treated group, 
followed by the being treated and well-controlled groups. 
These findings were observed in the ≥ 53  years old 
and women subgroups; however, the results were not 
significant in the < 53 years old and men subgroups of the 
being treated and well-controlled groups.
Table 1 General characteristics of participants
SD, standard deviation; BMI, body mass index
a  Independent T-test or Chi square test. Significance at P < 0.05
Characteristics Total participants P-value
Asthma Control
Age (mean, SD, y) 55.9 (8.7) 53.2 (8.4) < 0.001a
Sex (n, %) 24.4 (3.3) 23.9 (2.9) < 0.001a
 Men 952 (30.1) 54,772 (34.4)
 Women 2208 (69.9) 104,647 (65.6)
BMI (mean, SD, kg/m2) 24.4 (3.3) 23.9 (2.9) < 0.001a
Income (n, %) < 0.001a
 Missing, no response 471 (14.9) 20,322 (12.7)
 Lowest 1125 (35.6) 44,950 (28.2)
 Middle 996 (31.5) 59,632 (37.4)
 Highest 568 (18.0) 34,515 (21.7)
Smoking status (n, %) < 0.001a
 Nonsmoker 2344 (74.2) 116,244 (72.9)
 Past smoker 510 (16.1) 23,320 (14.6)
 Current smoker 306 (9.7) 19,855 (12.5)
Alcohol consumption (n, %) < 0.001a
 Non drinker 1804 (57.1) 81,011 (50.8)
 Past drinker 176 (5.6) 6091 (3.8)
 Current drinker 1180 (37.3) 72,317 (45.4)
Nutritional intake
 Total calories (kcal/d) 1722.6 (574.5) 1755.6 (582.6) 0.002a
 Protein (g/d) 57.8 (25.5) 59.7 (26.9) < 0.001a
 Fat (g/d) 26.5 (17.3) 28.1 (18.5) < 0.001a
 Carbohydrate (g/d) 309.1 (96.4) 311.8 (95.3) 0.117
 Calcium (mg/d) 449.3 (287.4) 450.4 (273.1) 0.839
 Phosphorus (mg/d) 878.5 (371.9) 898.6 (375.2) 0.003a
 Potassium (mg/d) 2233.8 (1142.2) 2271.1 (1109.4) 0.069
 Osteoporosis (n, %) 430 (13.6) 10,782 (6.8) < 0.001a
Table 2 Crude and  adjusted odds ratios (95% confidence 
interval) for osteoporosis in asthma and control groups
a  Logistic regression model, Significance at P < 0.05
b  Models adjusted for age, sex, income group, BMI, smoking, alcohol 
consumption, and nutritional intake (total calories, protein, fat, carbohydrate, 
calcium, phosphorous, and potassium intake)
Characteristics Odds ratios for osteoporosis
Crude P-value Adjustedb P-value
Total participants (n = 162,579)
 Asthma 2.17 (1.96–2.41) < 0.001a 1.74 (1.55–1.94) < 0.001a
 Control 1.00 1.00
Age < 53 years old (n = 80,370)
 Asthma 1.81 (1.37–2.40) < 0.001a 1.60 (1.20–2.12) 0.001a
 Control 1.00 1.00
Age ≥ 53 years old (n = 82,209)
 Asthma 1.90 (1.70–2.13) < 0.001a 1.80 (1.59–2.03) < 0.001a
 Control 1.00 1.00
Men (n = 55,724)
 Asthma 2.79 (1.81–4.30) < 0.001a 2.17 (1.40–3.36) 0.001a
 Control 1.00 1.00
Women (n = 106,855)
 Asthma 2.07 (1.86–2.31) < 0.001a 1.73 (1.54–1.94) < 0.001a
 Control 1.00 1.00
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Several asthma-related factors are associated 
with osteoporosis development. First, inflammatory 
cytokines, including TNF-α and IL-6, are associated 
with an increased risk of asthma [18, 19]. TNF-α and 
IL-6 have been shown to mediate inflammation, which 
contributes to bone resorption and osteoporosis through 
stimulation of osteoclast development and activity [20, 
21]. Second, increased inflammatory cytokine release can 
result in anorexia [22]. Therefore, patients with chronic 
inflammation are exposed to malnutrition, which leads 
to osteoporosis [23]. Third, there is a high prevalence 
of vitamin D deficiency among patients with asthma. 
A systematic review and meta-analysis reported that 
the prevalence of vitamin D deficiency was significantly 
greater among patients with asthma than among controls 
(relative risk = 1.59, 95% CI 1.07–2.36) [24]. Vitamin 
D deficiency causes secondary hyperparathyroidism; 
further, parathyroid hormone causes osteoblast 
activation. This stimulates preosteoclast transformation 
into mature osteoclasts, which causes osteopenia 
and osteoporosis, as well as increase the fracture risk 
[25]. Fourth, adults with asthma are less physically 
active compared with healthy individuals [26, 27] 
given that exercise and physical activities can trigger 
bronchoconstriction, which causes exertional dyspnea 
and other respiratory symptoms. Physical activity is 
an important factor for bone loss and osteoporosis 
prevention throughout an individual’s life [28]. Finally, 
there have been several reports of corticosteroid-induced 
osteoporosis. Corticosteroids (oral and inhaled) are the 
mainstay asthma management regimens due to their 
anti-inflammatory effect. They have been shown to 
reduce osteoblast function and proliferation, increase 
osteoblast and osteocyte apoptosis, and prolong the 
lifespan of osteoclasts [29]. Therefore, the correlation 
between asthma and osteoporosis could be secondary to 
the steroid treatment in patients with asthma.
We found that the ORs for osteoporosis were highest 
(1.96) in the not being treated asthma group. The 
correlation between asthma and osteoporosis could 
be dependent on the status of asthma management. 
Poor asthma management is associated with several 
factors, which may be associated with osteoporosis 
development. First, uncontrolled asthma is associated 
with an increased systemic inflammatory state. A study 
on cytokines in bronchoalveolar lavage fluid reported 
that patients with active asthma had increased TNF-α 
and IL-6 levels than healthy controls and stabilized 
patients with asthma [30]. Second, low circulating 
levels of 25-hydroxyvitamin D, which is the major 
circulating vitamin D metabolite, was associated 
with poor asthma management [31]. A meta-analysis 
reported that vitamin D supplementation reduced 
the rate of asthma exacerbation requiring treatment 
with systemic corticosteroids (adjusted incidence rate 
ratio = 0.74, 95% CI 0.56–0.97, P = 0.03) [32]. Third, 
low physical activity was found to be associated with 
poor asthma management. In Netherlands [27], a study 
divided patients with asthma according to their Asthma 
Control Questionnaire category and reported significant 
between-group differences in the physical activity level 
[1.58 ± 0.18 (well controlled) vs. 1.54 ± 0.13 (partially 
controlled) vs. 1.49 ± 0.13 (uncontrolled), P = 0.002], 
steps/day [8169 ± 3225 (well controlled) vs. 8244 ± 2621 
(partially controlled) vs. 6712 ± 3153 (uncontrolled), 
Table 3 Crude and  adjusted odds ratios (95% confidence 
interval) for  osteoporosis according to  the  condition 
of asthma management
a  Logistic regression model, Significance at P < 0.05
b  Models adjusted for age, sex, income group, BMI, smoking, alcohol 
consumption, and nutritional intake (total calories, protein, fat, carbohydrate, 
calcium, phosphorous, and potassium intake)
Characteristics Odds ratios for osteoporosis
Crude P-value Adjustedb P-value
Total participants (n = 155,506)
 Well controlled 1.71 (1.34–2.19) < 0.001a 1.43 (1.10–1.86) 0.008a
 Being treated 2.06 (1.72–2.47) < 0.001a 1.55 (1.28–1.89) < 0.001a
 Not being 
treated
2.36 (2.02–2.74) < 0.001a 1.96 (1.66–2.31) < 0.001a
 Control 1.00 1.00
Age < 53 years old (n = 76,816)
 Well controlled 1.35 (0.72–2.54) 0.356 1.20 (0.63–2.28) 0.579
 Being treated 1.88 (1.10–3.22) 0.022a 1.66 (0.96–2.88) 0.072
 Not being 
treated
1.97 (1.35–2.89) 0.001a 1.75 (1.18–2.58) 0.005a
 Control 1.00 1.00
Age ≥ 53 years old (n = 78,690)
 Well controlled 1.69 (1.29–2.23) < 0.001a 1.51 (1.13–2.02) 0.005a
 Being treated 1.59 (1.31–1.93) < 0.001a 1.56 (1.26–1.92) < 0.001a
 Not being 
treated
2.22 (1.87–2.63) < 0.001a 2.05 (1.71–2.47) < 0.001a
 Control 1.00 1.00
Men (n = 53,717)
 Well controlled N/A 0.996 N/A 0.996
 Being treated 2.30 (1.08–4.88) 0.031a 1.61 (0.75–3.45) 0.218
 Not being 
treated
4.00 (2.28–7.00) < 0.001a 3.43 (1.95–6.04) < 0.001a
 Control 1.00 1.00
Women (n = 102,335)
 Well controlled 1.58 (1.23–2.04) < 0.001a 1.49 (1.14–1.95) 0.003a
 Being treated 2.12 (1.75–2.57) < 0.001a 1.55 (1.27–1.91) < 0.001a
 Not being 
treated
2.16 (1.84–2.54) < 0.001a 1.88 (1.59–2.24) < 0.001a
 Control 1.00 1.00
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P = 0.005]; and time spent at vigorous exercise (> 6 
metabolic equivalents) [27 ± 22 (well controlled) vs. 
22 ± 13 (partially controlled) vs. 14 ± 13  min/day 
(uncontrolled), P < 0.001].
The ORs for osteoporosis were higher in the being 
treated asthma group (1.55) than in the well-controlled 
asthma group (1.43). This could be attributed to 
glucocorticoid-induced osteoporosis; however, the effect 
of inhaled corticosteroids (ICSs) on bone mineral density 
(BMD) in patients with asthma remains unclear [33, 34]. 
Moreover, oral corticosteroid treatment is known to 
reduce BMD and increase fracture risk [35]. On the other 
hand, some studies have reported an independent asthma 
effect on osteoporosis regardless of steroid treatment [14, 
36]. A Korean healthcare center-based study reported a 
significant BMD reduction (–0.53 ± 1.50 in the lumbar 
spine; − 0.46 ± 0.97 in the femur) in patients with 
positive AHR test results without a history of systemic 
corticosteroid use [14]. In a USA hospital-based study, 
patients with chronic lung disease (including chronic 
obstructive pulmonary disease [COPD] and asthma) 
who never had glucocorticoid treatment had an almost 
fourfold prevalence of osteoporosis compared with the 
control group [36]. Moreover, the well-controlled asthma 
group showed a significant correlation of asthma with 
osteoporosis. This could be attributed to the fact that 
asthma or the effects of previously used corticosteroids 
could be potential risk factors for osteoporosis.
In the women and age ≥ 53 years-old subgroups, there 
was a correlation found between asthma and osteoporosis 
regardless of the asthma management condition. Aging 
is also associated with an increased risk of osteoporosis 
[37]. Moreover, women are at increased estrogen-related 
osteoporosis risk since estrogen is crucially involved in 
bone growth and maturation, as well as in bone turnover 
regulation in adults [38]. Contrastingly, in the men 
and < 53  years-old subgroups, there was a significant 
positive association between asthma and osteoporosis 
in the not being treated asthma group only. Although 
we did not obtain information regarding menopause and 
hormonal replacement treatment in women, the rate of 
pre-menopausal women is likely to be higher at < 53 years 
old than in the older age subgroup. Moreover, the effect 
of non-treated asthma on osteoporosis was higher in 
men (OR = 3.43) than in women (OR = 1.88), which 
could be attributed to other factors, including systemic 
inflammation and physical activity, being more in 
apparent men than in women.
This study has several limitations. First, the disease 
history was based on self-reported questionnaires, 
which may have a possibility of recall bias or under/
over-reporting of the disease. However, self-reported 
disease history using questionnaires is widely accepted in 
large-scale population-based epidemiologic studies and 
structured questions were asked by trained interviewers 
in this cohort. In addition, a recent Korean study using 
the National Health Insurance Sharing Service database 
2002–2015 showed that the prevalence of asthma 
ranged from 1.55% to 2.21%  [39], which was similar to 
the prevalence of asthma in our results (1.94%). Second, 
the asthma management condition was also determined 
using a questionnaire. We could not assess the actual 
medication use, including oral corticosteroid and ICS. 
However, this was a large-scale population-based study; 
moreover, patients with asthma were divided to the 
well-controlled and not being treated asthma groups. 
Although none of the groups was treated with steroids, 
our findings indicate that untreated and neglected 
patients with asthma are at higher risk of osteoporosis. 
Third, we did not obtain information regarding asthma 
onset and duration, other comorbidities such as kidney 
disease, malabsorption, inflammatory bowel disease, 
and autoimmunity, serum vitamin D levels, other 
medications, and hormonal replacement treatment. 
However, we adjusted for nutritional intake, including 
total calories, protein, fat, carbohydrate, calcium, 
phosphorous, and potassium intake, since nutrition 
is an important modifiable factor that affects bone 
health [40]. Lastly, inflammatory cytokine levels were 
not measured. There is a need for further studies to 
determine the effects of systemic inflammatory response 
on osteoporosis development in patients with asthma.
Conclusion
Asthma was associated with osteoporosis in the Korean 
adult population. Patients with untreated asthma 
showed the highest ORs for osteoporosis. Clinicians 
should be aware of osteoporosis in patients with 
asthma, especially in those who are untreated and 
neglected.
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